Editas Medicine Net Debt Growth & History (EDIT)
Editas Medicine's net debt was −$69.9M for fiscal 2025.
View full Editas Medicine company overviewEditas Medicine annual net debt history
| Fiscal year | Period ended | Net debt | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | −$69.9M | −$30.9M | — |
| 2024 | 2024-12-31 | −$39.1M | $48.0M | — |
| 2023 | 2023-12-31 | −$87.1M | $10.5M | — |
| 2022 | 2022-12-31 | −$97.6M | $79.6M | — |
| 2021 | 2021-12-31 | −$177.2M | −$63.6M | — |
| 2020 | 2020-12-31 | −$113.5M | $95.6M | — |
| 2019 | 2019-12-31 | −$209.1M | −$106.7M | — |
| 2018 | 2018-12-31 | −$102.4M | $10.8M | — |
| 2017 | 2017-12-31 | −$113.2M | $37.0M | — |
| 2016 | 2016-12-31 | −$150.2M | — | — |
Editas Medicine quarterly net debt
| Fiscal quarter | Period ended | Net debt | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | −$110.6M | −$49.8M | — |
| Q1 2026 | 2026-03-31 | −$51.7M | $1.3M | — |
| Q4 2025 | 2025-12-31 | −$69.9M | −$30.9M | — |
| Q3 2025 | 2025-09-30 | −$86.9M | −$29.6M | — |
| Q2 2025 | 2025-06-30 | −$60.7M | −$35.0M | — |
| Q1 2025 | 2025-03-31 | −$53.0M | −$17.9M | — |
| Q4 2024 | 2024-12-31 | −$39.1M | $48.0M | — |
| Q3 2024 | 2024-09-30 | −$57.3M | −$9.4M | — |
| Q2 2024 | 2024-06-30 | −$25.7M | $157.9M | — |
| Q1 2024 | 2024-03-31 | −$35.1M | $56.8M | — |
| Q4 2023 | 2023-12-31 | −$87.1M | $10.5M | — |
| Q3 2023 | 2023-09-30 | −$47.9M | $141.5M | — |
| Q2 2023 | 2023-06-30 | −$183.6M | −$34.5M | — |
| Q1 2023 | 2023-03-31 | −$91.9M | $95.8M | — |
| Q4 2022 | 2022-12-31 | −$97.6M | $79.6M | — |
| Q3 2022 | 2022-09-30 | −$189.4M | $41.8M | — |
| Q2 2022 | 2022-06-30 | −$149.1M | $158.4M | — |
| Q1 2022 | 2022-03-31 | −$187.7M | $138.3M | — |
| Q4 2021 | 2021-12-31 | −$177.2M | −$63.6M | — |
| Q3 2021 | 2021-09-30 | −$231.2M | $21.7M | — |
| Q2 2021 | 2021-06-30 | −$307.6M | $149.4M | — |
| Q1 2021 | 2021-03-31 | −$326.0M | −$120.4M | — |
| Q4 2020 | 2020-12-31 | −$113.5M | $95.6M | — |
| Q3 2020 | 2020-09-30 | −$252.9M | −$165.7M | — |
| Q2 2020 | 2020-06-30 | −$457.0M | −$263.8M | — |
| Q1 2020 | 2020-03-31 | −$205.7M | −$66.1M | — |
| Q4 2019 | 2019-12-31 | −$209.1M | −$106.7M | — |
| Q3 2019 | 2019-09-30 | −$87.1M | −$8.1M | — |
| Q2 2019 | 2019-06-30 | −$193.2M | −$94.2M | — |
| Q1 2019 | 2019-03-31 | −$139.6M | $44.9M | — |
| Q4 2018 | 2018-12-31 | −$102.4M | $10.8M | — |
| Q3 2018 | 2018-09-30 | −$79.0M | −$26.1M | — |
| Q2 2018 | 2018-06-30 | −$99.0M | $11.2M | — |
| Q1 2018 | 2018-03-31 | −$184.5M | $133.1M | — |
| Q4 2017 | 2017-12-31 | −$113.2M | $37.0M | — |
| Q3 2017 | 2017-09-30 | −$52.9M | $115.0M | — |
| Q2 2017 | 2017-06-30 | −$110.2M | $84.8M | — |
| Q1 2017 | 2017-03-31 | −$317.6M | −$100.1M | — |
| Q4 2016 | 2016-12-31 | −$150.2M | — | — |
| Q3 2016 | 2016-09-30 | −$167.8M | — | — |
| Q2 2016 | 2016-06-30 | −$195.0M | — | — |
| Q1 2016 | 2016-03-31 | −$217.6M | — | — |
Editas Medicine net debt trends
Over the last five fiscal years, Editas Medicine's net debt increased from −$113.5M to −$69.9M, a change of $43.6M. The latest reported quarter, Q2 2026, shows −$110.6M.
What net debt means
Net debt compares a company’s interest-bearing debt with its cash and cash equivalents. Positive net debt means debt exceeds cash, while a negative value indicates the company has more cash than debt on this measure.
How net debt is calculated
TickerStat calculates net debt as total interest-bearing debt minus cash and cash equivalents at the same reporting-period end. Short-term investments are not subtracted because they are not included in the standardized cash series. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Editas Medicine source filings ↗